Real-world efficacy and safety of 177 Lu-DOTATATE in recurrent and inoperable meningiomas: early outcomes from a large single-centre cohort (EANM 2026) - Sep 29, 2026 - Abstract #OP-309; Pres time: Oct 19, 2026; 08:00 AM - 09:30 AM; Location: Hall F1; "177Lu-DOTATATE therapy showed favourable early disease control and acceptable tolerability in patients with recurrent or inoperable meningioma in a real-world setting.These findings support the use of 177Lu-DOTATATE in patients with otherwise limited treatment options.Further follow-up and larger patient cohorts are required to better define its role."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Brain Cancer • Immunology • Meningioma • Solid Tumor • SSTR
|
|
G. Sipka 1; K. Apro 1; A. Dobi 2; K. Hideghety 2; M. Balazsfi 3; P. Barzó 3; A. Bakos 1; I. Farkas 1; S. Nagy 1; N. Friedrich 1; B. Revesz 1; B. Bardoczi 1; R. Nemet 1; V. Zsiros 1; F. Timar 1; L. Pavics 1; Z. Besenyi 1
|